RT期刊文章SR电子T1胸膜胸膜血液发生：四环素的随机研究与Bleomycin JF欧洲呼吸杂志Jo Eur Respir J FD欧洲呼吸学会SP 2380 OP 2383 VO 10是10 A1 Aparicio，J A1的10A1 Martinez-Moragon。188bet官网地址Rogado，MC A1 Sanchis，J A1 Sanchis，F A1 Gil-Suay，V YR 1997 UL //www.qdcxjkg.com/content/10/10/2380.abstract/10/10/2380.Abstract Ab恶性胸腔积液通常用管胸瘘排水进行管理其次是化学血管瘤。已经显示四环素和博莱霉素，虽然两者既未明确地证明，但两者都没有明确地证明了另一致的优势。本研究的目的是在响应率和毒性概况方面比较这两个药剂。在单一中心进行预期的随机试验。1993年5月至1996年1月期间，分配了62例可恶性胸腔积液的可恶性胸腔积液，以在相同的引流程序后接收骨内四环素（1.5g）或玻璃霉素（60mg）。在两个组中，人口统计学，临床和流体参数数据都是相当的。响应在胸膜瘤病术后1,3和6个月评估。两组之间的平均存活率和复发时间没有差异。 No statistically significant differences were found in terms of efficacy at each evaluation time. Overall, 16 (52%) and 20 (64%) patients had a recurrence of pleural effusion during follow-up in the tetracycline and bleomycin arms, respectively. Fever was most common in bleomycin-treated patients (p=0.024) while pain was most frequent in the tetracycline arm (nonsignificant). Since no study agent was superior to the other in this trial, we suggest that economic costs, drug availability and medical skill should be considered in the choice of a sclerosing agent.